Akums Introduces DCGI Approved Medication For Resistant Hypertension Treatment

Akums Drugs and Pharmaceuticals has recently launched a medication approved by the Drugs Controller General of India (DCGI) for the treatment of resistant hypertension., the company informed in a press statement on Saturday. Hypertension, a widespread health concern globally, poses significant risks of mortality and long-term morbidity.

The newly introduced medication, Amlodipine, Telmisartan and Metoprolol (ER) Film Coated Tablets, is a fixed-dose combination (FDC) designed to manage uncontrolled essential hypertension in individuals with stable coronary artery disease. By integrating the therapeutic benefits of three established medications into a single tablet, Akums aims to provide a comprehensive solution for blood pressure control.

Sanjeev Jain, Joint MD of Akums Drugs and Pharmaceuticals, expressed confidence in the potential of this formulation to revolutionise hypertension management. "We believe that this formulation has the potential to improve the way we manage hypertension," Jain stated.

The press statement further explained that  FDC combines the mechanisms of action of calcium channel blockers, angiotensin II receptor antagonists, and beta-adrenergic blockers to offer an effective approach to blood pressure regulation. By blocking voltage-dependent L-type calcium channels, Amlodipine induces vasodilation and reduces vascular smooth muscle contractility, thereby lowering blood pressure. Telmisartan selectively inhibits the angiotensin II AT1 receptor subtype, promoting blood vessel relaxation. Additionally, Metoprolol (ER), a cardio-selective beta-1-adrenergic receptor inhibitor, decreases cardiac output through negative inotropic and chronotropic effects.

Sandeep Jain, another Joint MD of Akums Drugs and Pharmaceuticals, emphasised the company's commitment to enhancing patient outcomes and improving the quality of life for individuals with hypertension. "This new FDC embodies our commitment to improving patient outcomes and enhancing the quality of life for individuals battling hypertension," said Sandeep Jain.

The introduction of Amlodipine, Telmisartan and Metoprolol (ER) Film Coated Tablets marks a significant advancement in cardiovascular care, offering a convenient and comprehensive solution for patients with resistant hypertension, the statement added.